New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
16:40 EDTTKPYYMillennium and Takeda report data from Phase I trial of ADCETRIS
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited announced results from two arms of a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed mature T-cell lymphoma, MTCL, patients, including patients with systemic anaplastic large cell lymphoma, sALCL. These data were presented at the 54th American Society of Hematology, ASH, Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate, ADC, directed to CD30. ADCETRIS is not approved for use in the front-line treatment of MTCL.
News For TKPYY From The Last 14 Days
Check below for free stories on TKPYY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
10:34 EDTTKPYYApricus Biosciences reports Takeda accepts first shipment of Vitaros
Subscribe for More Information
April 8, 2014
09:03 EDTTKPYYSeattle Genetics to receive milestone payments from Takeda on Adcetris
Subscribe for More Information
08:39 EDTTKPYYTakeda to challenge award of $6B in punitive damages, Lilly ordered to pay $3B
Takeda Pharmaceuticals (TKPYY) announced last night that in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America the jury found in favor of the plaintiffs and awarded $1.475M in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly (LLY). The jury also awarded $6B in punitive damages from Takeda and $3B from co-defendant, Eli Lilly. “Takeda respectfully disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal. We have empathy for the Allens, but we believe the evidence did not support a finding that ACTOS caused his bladder cancer. We also believe we demonstrated that Takeda acted responsibly with regard to ACTOS,” said Kenneth Greisman, senior vice president, general counsel, Takeda. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use